All In Biotech

Drug Trial Radar · NCT04517435

ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

An Open-Label, Phase I/II Study of ME-401 and R-CHOP in Newly Diagnosed Diffuse Large B-Cell Lymphoma

Last checked: Nov 19, 2026Latest source record: Feb 7, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

13

Actual

Start

Apr 28, 2021

Primary completion

May 17, 2023

Study completion May 17, 2023

Sponsor

Lead sponsor
Deepa JagadeeshAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Case Comprehensive Cancer Center
First posted
Aug 18, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to evaluate if ME-401 can improve the treatment of patients with diffuse large b-celllymphoma (DLBCL). Many patients with DLBCL that are treated with the standard of care (R-CHOP) are cured. However, a little less than half of patients will have their cancer come back despite being treated. Once DLBCL comes back, it is much harder to treat and treatment is much more aggressive. This study will combine ME-401 with R-CHOP. There are 2 parts to this study: part1 referred to as phase I and part 2 referred to as phase 2. The goal of the phase I study is to find the safest dose to give patients in combination with R-CHOP. The goal of the phase 2 study is to use the safest dose (found in phase 1) in combination with R-CHOP to see if it decreases the rate of cancer coming back after it is treated.

Conditions

  • Diffuse Large B-Cell Lymphoma

Interventions

  • ME-401Drug

    ME-401 (60 mg) will be given by mouth every 21 days for 6 cycles on days 1-4 (dose level 1) OR days 1-7 (dose level 2) of a 21 day cycle. Dose escalation will be performed in a standard 3+3 design

  • RituximabDrug

    375 mg/m2 IV/subcutaneous rituximab day 1 of 21-day cycle. First dose of rituximab will be given IV and subsequent doses can be either IV or SQ based on institutional guidelines.

  • CyclophosphamideDrug

    750 mg/m2 IV Cyclophosphamide day 1 of 21-day cycle

  • DoxorubicinDrug

    50 mg/m2 IV Doxorubicin day 1 of 21-day cycle

  • VincristineDrug

    1.4 mg/m2 (max 2 mg) IV Vincristine

  • PrednisoneDrug

    100mg PO Prednisone Days 1-5 of 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Number of Clinically Significant Non-hematologic Grade 3 or 4 Treatment-related AEs or Hematologic Grade 3 or 4 Treatment Related AEsTime frame: Up to 24 months after treatment
  2. Phase II: Progression Free Survival (PFS) Assessed by Lugano CriteriaTime frame: 24 months (2 years)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center

    Cleveland, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.